文献速递帕金森病与运动障碍癫痫认知障碍与痴呆

经颅聚焦超声技术的当前治疗、挑战与未来方向综述

A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment.
PubMed 文献 · JAMA Neurol · 2018-01-01

该综述回顾了经颅聚焦超声(FUS)的技术基础、现有神经科应用及未来进展。检索PubMed近10年文献,从2855条记录中筛选243篇,最终定性review 86篇全文。FUS已获批治疗难治性特发性震颤,并在帕金森病运动障碍、癫痫、脑肿瘤等领域探索中。

要点

  • 中频(650 kHz)换能器可产生直径4-6 mm、精度<2 mm的精确脑病灶。
  • 低频(220 kHz)换能器联合微泡可潜在实现靶向药物递送。
  • 亚阈值超声神经调控可探查传统电刺激难以触及的脑区。

核心结论

  • 经颅聚焦超声的消融与非消融应用均无创,适合不适合传统手术的特定患者。
  • 未来影像与超声算法进步将提升该技术的安全性和有效性。

研究设计与样本

  • 综述检索PubMed近10年文献,使用「transcranial ultrasound」「focused ultrasound」「neurological applications」等词。
  • 从2855条唯一记录中筛选243篇文献,排除体外研究或非神经应用摘要后,定性review 86篇全文。

主要发现

  • 换能器设计与电子相位校正的进步使经颅治疗中超声可高效聚焦。
  • 中频(650 kHz)换能器可产生直径4-6 mm、精度<2 mm的小而精确的脑病灶。
  • 治疗监测通过「实时」解剖热成像和临床反馈实现。
  • 运动障碍疾病的初步临床应用结果令人鼓舞,癫痫、神经行为与认知障碍等新应用正在探索。
  • 低频(220 kHz)换能器联合微泡可潜在实现靶向药物递送,用于阿尔茨海默病和脑肿瘤等新应用。

临床怎么用

  • 经颅聚焦超声消融已获批用于治疗难治性特发性震颤。
  • 该技术适用于不适合传统手术选项的特定患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Magnetic resonance imaging-guided focused ultrasound ablation has been approved for the treatment of refractory essential tremor and is being studied for other neurological indications, including dyskinesias and tremor in Parkinson disease, dystonia, neuropathic pain, obsessive-compulsive disorder, epilepsy, and brain tumors. OBJECTIVE: To review the scientific foundations of FUS technology, existing neurological applications, and future advances. EVIDENCE REVIEW: PubMed was searched for the past 10 years using the terms "transcranial ultrasound," "focused ultrasound," and "neurological applications." Relevant references were selected from the author's reference collection. From the 2855 unique records, 243 publications were screened. After excluding abstracts detailing in vitro studies or non-neurological applications, 86 full texts were retrieved for qualitative review. FINDINGS: Advances in the transducer design and electronic phase correction have allowed efficient focusing of ultrasounds for transcranial treatment. The mid-frequency (650 kHz) transducer can make small (4-6 mm in diameter) and precise (accuracy of <2 mm) brain lesions. The treatment monitoring is achieved via "live" anatomical thermography imaging and clinical feedback. The initial results from its clinical application in movement disorders are encouraging. Emerging applications in epilepsy and neurobehavioral and cognitive disorders are being explored. The low-frequency (220 kHz) transducer coupled with microbubbles can potentially enable targeted drug delivery for novel applications, such as Alzheimer disease and brain tumors. Finally, neuromodulation with subthreshold sonications may allow the interrogation of brain areas previously not accessible for electrical stimulation. CONCLUSIONS AND RELEVANCE: Transcranial focused ultrasound for both ablative and nonablative applications is noninvasive, making it suitable for selected patients who are not candidates for conventional surgical options. Future advancements in imaging and sonication algorithms will improve the safety and efficacy of this technology.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Krishna V, Sammartino F, Rezai A, et al. A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment. JAMA Neurol. 2018. PMID: 29228074. doi:10.1001/jamaneurol.2017.3129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。